A Phase 3 interventional study of Inclisiran in Acute Coronary Syndrome, sponsored by Novartis Pharmaceuticals. Completed at 88 sites in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-10-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Acute Coronary Syndrome by Novartis — 2 open to participants now, 2 under way, 1 of them phase 3. Acute Coronary Syndrome · Novartis.
Among the 11 studies in Acute Coronary Syndrome by Novartis, this one is the 6th largest by enrollment, is the only one that started in 2021, is one of 8 in phase 3, and was the 8th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.
Browse Acute Coronary Syndrome studies →2 of the 11 studies in Acute Coronary Syndrome by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Argentina, Australia, Canada and 11 more countries
Ages 18+
Novartis Pharmaceuticals
Ages 18–100
By country, each count listing its studies:
Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 8 · Phase 4 1
First in 2003; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 400 is above the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 400 across the 11 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
1 of the studies in Acute Coronary Syndrome by Novartis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-02-11 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Acute Coronary Syndrome by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to study the effectiveness of implementation of a systematic LDL-C management pathway including treatment with inclisiran in participants who have experienced a recent acute coronary syndrome (ACS) and have an increased LDL-cholesterol (≥70 mg/dL) despite being treated with a statin drug.
This was a randomized, parallel-group, open-label, multicenter, 1-year (30-day Screening Period and 330-day Treatment Period) study comparing an LDL-C management strategy including inclisiran + usual care to usual care alone. Approximately 384 participants were planned to be randomized 1:1 to aggressive LDL-C management with inclisiran + usual care (intervention arm) (3 inclisiran doses) or usual care (control arm). Usual care could have included addition of ezetimibe, bempedoic acid, PCSK9-inhibiting monoclonal antibodies, and/or commercially available inclisiran
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inclisiran sodium 300 mg / 1.5 ml (equivalent to 284 mg of inclisiran)
Drug: Inclisiran
Usual Care Alone
Inclisiran sodium 300 mg / 1.5 ml (equivalent to 284 mg of inclisiran)
Also known as: KJX839
Percent Change From Baseline to Day 330 in LDL-C
Percent change from baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Day 330
Time frame: Baseline and Day 330
Achievement of LDL-C < 70 mg/dL at Day 330
Percentage of participants achieving Low-Density Lipoprotein Cholesterol (LDL-C) \< 70 mg/dL at Day 330
Time frame: Day 330
Absolute Change From Baseline in LDL-C
Absolute change from baseline in low-density lipoprotein cholesterol (LDL-C) by visit
Time frame: Baseline, Day 90, Day 270 and Day 330
Average Percent Change From Baseline in LDL-C Levels
Average percent change from baseline in low-density lipoprotein cholesterol (LDL-C) levels to each post-baseline visit
Time frame: Baseline, from Day 90 to Day 330
Average Absolute Change From Baseline in LDL-C Levels
Average absolute change from baseline in low-density lipoprotein cholesterol (LDL-C) levels to each post-baseline visit
Time frame: Baseline, From Day 90 to Day 330
Achieving ≥50% Reduction From Baseline in LDL-C
Percentage of participants achieving ≥50% reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at Day 330
Time frame: Baseline, Day 330
Achieving LDL-C < 100 mg/dL and LDL-C < 55 mg/dL
Percentage of participants achieving low-density lipoprotein cholesterol (LDL-C) \<100 mg/dL (among the subset of participants with baseline LDL-C \>= 100 mg/dL) and LDL-C \< 55 mg/dL at Day 330
Time frame: Day 330
Percent Change in Lipids and Other Lipoproteins From Baseline to Day 330
Percent change in apolipoprotein B, very-low-density lipoprotein (VLDL), non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol, lipoprotein(a) (Lp\[a\]), HDL-C and triglycerides from baseline to Day 330
Time frame: Baseline and Day 330
Absolute Change in Lipids and Other Lipoproteins From Baseline to Day 330
Absolute change in apolipoprotein B, very-low-density lipoprotein (VLDL), non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol, HDL-C and triglycerides from baseline to Day 330
Time frame: Baseline and Day 330
Absolute Change in Lp[a] From Baseline to Day 330
Absolute change in lipoprotein(a) (Lp\[a\]) from baseline to Day 330
Time frame: Baseline and Day 330
Intensity of Lipid Lowering Therapy
Percentage of participants by intensity of lipid lowering therapy (dose decrease, increase or no change)
Time frame: Baseline and Day 330
Proportion of Days Covered
Total number of days on either statin, ezetimibe, or PCSK9 inhibiting monoclonal antibody therapies divided by total number of study days. If a participant did not take any of the 3 medications, then the total number of days was assumed to be zero.
Time frame: Baseline through last date of participation, up to 330 Days
Discontinuation of Statin Therapy
Percentage of participants discontinuing statin therapy. Discontinuation of statin therapy was defined as no statin use ≥ 30 days before the end-of-study visit. Participants for whom it could not be ascertained that they were on statin therapy at the end of study or who discontinued from the study early were assumed to have discontinued statin therapy.
Time frame: Baseline and Day 330
This study was conducted at 87 study centers. Of the 201 participants randomized to inclisiran + usual care, 1 participant was randomized erroneously and did not receive inclisiran. Of the 199 participants randomized to usual care, 3 participants received commercially available inclisiran as part of their concomitant medications.
| Milestone | Inclisiran With Usual Care | Usual Care |
|---|---|---|
| Started | 201 | 199 |
| Full analysis set | 201 | 199 |
| Safety set | 203 | 197 |
| Completed | 183 | 173 |
| Not completed | 18 | 26 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Lost to follow-up | 13 | 9 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Protocol deviation | 2 | 1 |
| Withdrew: Subject decision | 1 | 8 |
| Withdrew: Withdrew consent | 0 | 4 |
| Withdrew: Missing | 1 | 0 |
Percent change from baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Day 330
| Percent change in LDL-C | Inclisiran With Usual Care | Usual Care |
|---|---|---|
| Percent Change From Baseline to Day 330 in LDL-C | -45.6 (-51.5 to -39.6) | 1.4 (-4.7 to 7.5) |
Percentage of participants achieving Low-Density Lipoprotein Cholesterol (LDL-C) \< 70 mg/dL at Day 330
| Percentage of participants | Inclisiran With Usual Care | Usual Care |
|---|---|---|
| Achievement of LDL-C < 70 mg/dL at Day 330 | 66.7 (59.2 to 74.1) | 28.1 (21.0 to 35.3) |
Absolute change from baseline in low-density lipoprotein cholesterol (LDL-C) by visit
| mg/dL | Inclisiran With Usual Care | Usual Care |
|---|---|---|
| Day 90 | -44.2 (-47.9 to -40.5) | -2.2 (-6.0 to 1.6) |
| Day 270 | -34.6 (-39.2 to -30.1) | -3.8 (-8.6 to 1.0) |
| Day 330 | -41.2 (-45.9 to -36.5) | -3.5 (-8.3 to 1.4) |
Average percent change from baseline in low-density lipoprotein cholesterol (LDL-C) levels to each post-baseline visit
| Average percent change in LDL-C | Inclisiran With Usual Care | Usual Care |
|---|---|---|
| Average Percent Change From Baseline in LDL-C Levels | -44.3 (-48.5 to -40.1) | 2.4 (-1.8 to 6.7) |
Average absolute change from baseline in low-density lipoprotein cholesterol (LDL-C) levels to each post-baseline visit
| mg/dL | Inclisiran With Usual Care | Usual Care |
|---|---|---|
| Average Absolute Change From Baseline in LDL-C Levels | -40.0 (-43.6 to -36.4) | -2.7 (-6.4 to 1.0) |
Percentage of participants achieving ≥50% reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at Day 330
| Percentage of participants | Inclisiran With Usual Care | Usual Care |
|---|---|---|
| Achieving ≥50% Reduction From Baseline in LDL-C | 45.3 (38.4 to 52.2) | 6.5 (3.1 to 10.0) |
Percentage of participants achieving low-density lipoprotein cholesterol (LDL-C) \<100 mg/dL (among the subset of participants with baseline LDL-C \>= 100 mg/dL) and LDL-C \< 55 mg/dL at Day 330
| Percentage of participants | Inclisiran With Usual Care | Usual Care |
|---|---|---|
| Achieving LDL-C < 100 mg/dL | 75.8 (65.1 to 86.5) | 40.4 (27.0 to 53.7) |
| Achieving LDL-C < 55 mg/dL | 54.2 (47.3 to 61.1) | 13.6 (8.8 to 18.3) |
Percent change in apolipoprotein B, very-low-density lipoprotein (VLDL), non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol, lipoprotein(a) (Lp\[a\]), HDL-C and triglycerides from baseline to Day 330
| Percent change | Inclisiran With Usual Care | Usual Care |
|---|---|---|
| apolipoprotein B | -35.5 (-40.6 to -30.5) | 2.0 (-3.2 to 7.1) |
| VLDL Cholesterol | 5.7 (-1.0 to 12.3) | 12.1 (5.2 to 18.9) |
| non-HDL-Cholesterol | -35.2 (-39.6 to -30.8) | 2.5 (-2.0 to 7.1) |
| Total Cholesterol | -21.4 (-24.7 to -18.1) | 4.1 (0.6 to 7.5) |
| Lp[a] | -10.4 (-25.9 to 5.0) | 5.9 (-9.7 to 21.6) |
| HDL-Cholesterol | 14.0 (10.8 to 17.3) | 10.6 (7.2 to 13.9) |
| triglycerides | 7.3 (0.1 to 14.4) | 12.3 (4.9 to 19.6) |
Absolute change in apolipoprotein B, very-low-density lipoprotein (VLDL), non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol, HDL-C and triglycerides from baseline to Day 330
| mg/dL | Inclisiran With Usual Care | Usual Care |
|---|---|---|
| apolipoprotein B | -31.0 (-34.2 to -27.8) | -2.6 (-5.8 to 0.6) |
| VLDL Cholesterol | -0.4 (-2.0 to 1.3) | 1.8 (0.0 to 3.5) |
| non-HDL-Cholesterol | -41.4 (-46.5 to -36.3) | -1.3 (-6.5 to 4.0) |
| total Cholesterol | -35.2 (-40.5 to -30.0) | 2.5 (-2.9 to 7.9) |
| HDL-Cholesterol | 5.7 (4.3 to 7.1) | 3.8 (2.4 to 5.3) |
| triglycerides | 1.1 (-8.7 to 10.8) | 9.8 (-0.3 to 19.9) |
Absolute change in lipoprotein(a) (Lp\[a\]) from baseline to Day 330
| nmol/L | Inclisiran With Usual Care | Usual Care |
|---|---|---|
| Absolute Change in Lp[a] From Baseline to Day 330 | -19.3 (-26.2 to -12.4) | -5.3 (-12.2 to 1.7) |
Percentage of participants by intensity of lipid lowering therapy (dose decrease, increase or no change)
| Percentage of participants | Inclisiran With Usual Care | Usual Care |
|---|---|---|
| Decrease in statin intensity | 9.8 (5.9 to 15.0) | 4.6 (2.0 to 8.9) |
| No change in statin intensity | 89.1 (83.7 to 93.2) | 92.5 (87.6 to 96.0) |
| Increase in statin intensity | 1.1 (0.1 to 3.9) | 2.9 (0.9 to 6.6) |
Total number of days on either statin, ezetimibe, or PCSK9 inhibiting monoclonal antibody therapies divided by total number of study days. If a participant did not take any of the 3 medications, then the total number of days was assumed to be zero.
| Proportion of days | Inclisiran With Usual Care | Usual Care |
|---|---|---|
| Proportion of Days Covered | 0.926 (0.900 to 0.953) | 0.965 (0.939 to 0.992) |
Percentage of participants discontinuing statin therapy. Discontinuation of statin therapy was defined as no statin use ≥ 30 days before the end-of-study visit. Participants for whom it could not be ascertained that they were on statin therapy at the end of study or who discontinued from the study early were assumed to have discontinued statin therapy.
| Percentage of participants | Inclisiran With Usual Care | Usual Care |
|---|---|---|
| Discontinuation of Statin Therapy | 14.5 (9.2 to 19.7) | 18.0 (12.3 to 23.6) |
Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 330 days.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inclisiran + Usual Care | 0/203 (0%) | 32/203 (15.8%) | 52/203 (25.6%) |
| Usual Care | 2/197 (1%) | 34/197 (17.3%) | 35/197 (17.8%) |
| Event | Inclisiran + Usual Care | Usual Care |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 8/203 | 6/197 |
| AnaemiaBlood and lymphatic system disorders | 1/203 | 2/197 |
| Angina pectorisCardiac disorders | 2/203 | 2/197 |
| Angina unstableCardiac disorders | 0/203 | 2/197 |
| Cardiac arrestCardiac disorders | 0/203 | 2/197 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/203 | 2/197 |
| PneumoniaInfections and infestations | 0/203 | 2/197 |
| FallInjury, poisoning and procedural complications | 0/203 | 2/197 |
| Ischaemic strokeNervous system disorders | 0/203 | 2/197 |
| Cardiac failure acuteCardiac disorders | 2/203 | 0/197 |
| Event | Inclisiran + Usual Care | Usual Care |
|---|---|---|
| Non-cardiac chest painGeneral disorders | 8/203 | 10/197 |
| Injection site painGeneral disorders | 10/203 | 0/197 |
| COVID-19Infections and infestations | 10/203 | 9/197 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/203 | 3/197 |
| Angina pectorisCardiac disorders | 7/203 | 3/197 |
| Upper respiratory tract infectionInfections and infestations | 6/203 | 6/197 |
| Blood creatine phosphokinase increasedInvestigations | 5/203 | 6/197 |
| DizzinessNervous system disorders | 6/203 | 6/197 |
| Age, Continuous(years) | Inclisiran With Usual Care | Usual Care | Total |
|---|---|---|---|
| Mean | 60.8 ± 10.90 | 60.2 ± 11.69 | 60.5 ± 11.29 |
| Sex: Female, Male(Participants) | Inclisiran With Usual Care | Usual Care | Total |
|---|---|---|---|
| Female | 63 | 53 | 116 |
| Male | 138 | 146 | 284 |
| Race/Ethnicity, Customized(Participants) | Inclisiran With Usual Care | Usual Care | Total |
|---|---|---|---|
| White | 166 | 167 | 333 |
| Black or African American | 25 | 24 | 49 |
| Asian | 6 | 3 | 9 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| American Indian or Alaska Native | 1 | 0 | 1 |
| Unknown | 2 | 4 | 6 |
| Multiple | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jun 2021 to primary completion in Aug 2024, 37 months.
Results were first posted in Aug 2025, 1 year after primary completion.
Of 39 phase 3 interventional studies under Acute Coronary Syndrome, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 52. This study's 37 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inclisiran